Showing 2636 results
- https://www.novartis.com/diseases/malaria
- https://www.novartis.com/news/media-releases/novartis-and-medicines-malaria-venture-announce-positive-efficacy-and-safety-data-novel-treatment-babiesThere is currently no evidence-based treatment for the smallest babies with malaria The CALINA study tested a new ratio and dose of Coartem® (artemether- lumefantrine) to account for metabolic…
- https://www.novartis.com/news/media-releases/novartis-radioligand-therapy-lutathera-fda-approved-first-medicine-specifically-pediatric-patients-gastroenteropancreatic-neuroendocrine-tumorsApproval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic…
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
https://www.novartis.com/news/media-releases/novartis-delivers-double-digit-sales-growth-and-core-margin-expansion-q1-fy-2024-guidance-raisedAd hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including…- https://www.novartis.com/news/media-releases/novartis-au-premier-trimestre-croissance-deux-chiffres-du-chiffre-daffaires-et-expansion-de-la-marge-core-hausse-des-previsions-pour-2024Annonce événementielle au sens de l’art. 53 RCRésultats du premier trimestre (T1)Chiffre d’affaires net en hausse de +11% (tcc1, +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD)…
- https://www.novartis.com/news/media-releases/novartis-erzielt-im-ersten-quartal-ein-zweistelliges-umsatzwachstum-und-steigert-die-kerngewinnmarge-prognose-fur-das-geschaftsjahr-2024-erhohtAd-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten…
- https://www.novartis.com/news/media-releases/novartis-kesimpta-six-year-efficacy-data-show-substantial-benefits-recently-diagnosed-treatment-naive-people-relapsing-multiple-sclerosisContinuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis…
- https://www.novartis.com/news/media-releases/new-novartis-fabhalta-iptacopan-data-show-clinically-meaningful-and-statistically-significant-proteinuria-reduction-383-versus-placebo-patients-iga-nephropathy-iganAPPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare…
- https://www.novartis.com/news/media-releases/novartis-tender-offer-morphosys-ag-commencesBasel, April 11, 2024 – Novartis published today the offer document for the voluntary public takeover offer by its wholly owned subsidiary Novartis BidCo AG for all outstanding shares of MorphoSys AG…
- https://www.novartis.com/news/media-releases/new-novartis-data-show-early-addition-twice-yearly-leqvio-inclisiran-following-maximally-tolerated-statin-therapy-significantly-reduces-ldl-c-ascvd-patients-real-world-settingV-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal on statin therapy alone led to significant…
Pagination
- ‹ Previous page
- 1
- …
- 240
- 241
- 242
- 243
- 244
- 245
- 246
- …
- 264
- › Next page